News of Note—European Commission, Sinovac drama and more

non
In this week's news of note, Vaccines Europe urges the European Commission to play a more active role in ensuring vaccines supply. (Pixabay)

Here is some other vaccine news of note for the week.

> The European Commission could play a more active role in improving the regulatory framework for vaccines to avoid supply issues, according to the European vaccine industry group Vaccines Europe. Euractiv article

> Chinese vaccine maker Sinovac accused Sinobioway and "dozens of unnamed individuals" of trying to take over its manufacturing site, including by cutting power there multiple times and preventing employees from getting to their work stations. Release

> Advaxis, which develops neoantigen cancer vaccines, hired former Rosetta Genomics chief Kenneth Berlin to fill its vacant CEO post, among other executive moves. FierceBiotech article

> The Sabin Vaccine Institute awarded Paul Offit, M.D., the 2018 Albert B. Sabin Gold Medal for his work in co-inventing oral rotavirus vaccine RotaTeq and leading advocacy for immunization. Release

> Celldex, the developer of failed cancer vaccine Rintega, is laying off 20% of its workforce. FierceBiotech article.

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.